Medpace Holdings, Inc. (MEDP) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MEDP Revenue Growth
Revenue Breakdown (FY 2025)
MEDP's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MEDP Revenue Analysis (2014–2025)
As of May 6, 2026, Medpace Holdings, Inc. (MEDP) generated trailing twelve-month (TTM) revenue of $2.68 billion, reflecting exceptional growth of +26.5% year-over-year. The most recent quarter (Q1 2026) recorded $706.6 million in revenue, down 0.3% sequentially.
Looking at the longer-term picture, MEDP's 5-year compound annual growth rate (CAGR) stands at +22.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $2.53 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows MEDP's business is primarily driven by Oncology (30%), Metabolic (29%), and Other (16%).
When compared to Healthcare sector peers including ICLR (-2.5% YoY), CRL (-0.9% YoY), and PRA (-3.9% YoY), MEDP has underperformed the peer group in terms of revenue growth. Compare MEDP vs ICLR →
MEDP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MEDPCurrent | $2.7B | +26.5% | +22.3% | 21.1% | |
 ICLR | $8.3B | -2.5% | +24.2% | 13.3% | |
 CRL | $4.0B | -0.9% | +6.5% | 12.6% | |
 PRA | $1.1B | -3.9% | +4.4% | 6.6% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% | |
 IQV | $16.3B | +7.3% | +7.5% | 14.0% |
MEDP Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.53B | +20.0% | $760.6M | 30.1% | $534.9M | 21.1% |
| 2024 | $2.11B | +11.8% | $656.3M | 31.1% | $446.9M | 21.2% |
| 2023 | $1.89B | +29.2% | $524.5M | 27.8% | $336.8M | 17.9% |
| 2022 | $1.46B | +27.8% | $432.4M | 29.6% | $278.7M | 19.1% |
| 2021 | $1.14B | +23.4% | $328.2M | 28.7% | $198.6M | 17.4% |
| 2020 | $925.9M | +7.5% | $278.7M | 30.1% | $167.0M | 18.0% |
| 2019 | $861.0M | +22.2% | $245.7M | 28.5% | $127.3M | 14.8% |
| 2018 | $704.6M | +61.5% | $215.5M | 30.6% | $101.0M | 14.3% |
| 2017 | $436.2M | +3.5% | $174.7M | 40.1% | $64.9M | 14.9% |
| 2016 | $421.6M | +17.4% | $172.1M | 40.8% | $52.5M | 12.5% |
Full MEDP Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See MEDP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MEDP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MEDP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMEDP — Frequently Asked Questions
Quick answers to the most common questions about buying MEDP stock.
Is MEDP's revenue growth accelerating or slowing?
MEDP revenue is accelerating at +26.5% year-over-year, exceeding the 5-year CAGR of +22.3%. TTM revenue reached $2.7B. Growth momentum has increased versus prior periods.
What is MEDP's long-term revenue growth rate?
Medpace Holdings, Inc.'s 5-year revenue CAGR of +22.3% reflects the sustained expansion pattern. Current YoY growth of +26.5% is above this long-term average.
How is MEDP's revenue distributed by segment?
MEDP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.